secwatch.observer — SEC 8-K summary
======================================

Issuer:     SUPERNUS PHARMACEUTICALS, INC. (SUPN)
CIK:        0001356576
Form:       8-K
Filed at:   2026-08-03T10:43:48+00:00
Accession:  0001104659-26-089425
Event type: m_and_a
Sentiment:  neutral
Materiality: 0.90
Item codes: 1.01, 5.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Supernus to merge with Indivior in all-stock deal; Indivior holders to own 56.5%
--------------------------------------------------------------------------------

- Each Supernus share converts to 1.5401 Indivior shares; fixed exchange ratio, no adjustment for market changes.
- Indivior stockholders to own ~56.5% of combined company; Supernus stockholders ~43.5% on fully diluted basis.
- Indivior to pay $1B special dividend to its stockholders pre-closing, funded by $650M Citibank term loan.
- Combined company renamed Supernus, Inc., trades under SUPN; Jack Khattar CEO, Tim Dec CFO; board split 4-4.
- Termination fees: $101M from Supernus, $174M from Indivior under specified circumstances.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1356576/000110465926089425/0001104659-26-089425-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1356576/000110465926089425/tm2622009d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-089425

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer